€47.5m market cap
€1.21 last close
Based in Spain, ADL Bionatur Solutions provides contract manufacturing of fermentation-based biochem products and antibiotics. It also develops and licenses its own portfolio of OTC and prescription animal health products, including probiotics and vaccines.
Investment summary
ADL Bionatur Solutions provides contract manufacturing (CMO) of fermentation-based products and services focused on the health, beauty and wellness sectors. It has established CMO/active pharmaceutical ingredient business lines and its own development line of innovative products. ADL-BS has 2,400m3 of total fermentation capacity available and indicates that over 85% of available capacity has been contractually committed for the next two years. It guided for €50m in 2019 sales (vs €25m in 2018) and positive EBITDA, after reporting 9M19 sales of €33.2m, and €2.2m in adjusted EBITDA.
Y/E Dec |
Revenue (€m) |
EBITDA (€m) |
PBT (€m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 12.8 | (10.4) | (12.7) | (251.65) | N/A | N/A |
| 2018A | 25.3 | (12.5) | (16.3) | (43.16) | N/A | N/A |
| 2019E | 53.0 | 3.8 | (1.6) | (4.06) | N/A | N/A |
| 2020E | 71.6 | 10.5 | 4.2 | 10.76 | 11.2 | 5.6 |
Industry outlook
We estimate the ADL unit’s solid pipeline of CMO contracts will contribute to sustainable long-term growth. We calculate ADL H119 net debt of approximately €50.2m, including an €8.7m loan from its majority shareholder. In August 2019, ADL received €25m in debt financing, which was intended to fund its business plan for the next four years. While facilities remain operational during the pandemic, ADL cited a slowdown in its supply chain and has sought a temporary employment reduction for c 300 staff.
Last updated on 03/06/2020
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net debt (€m) | 57.1 |
| Forecast gearing ratio (%) | 295 |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Pilar de la Huerta | CEO |
You may also be interested in…
- 4SC
- Abliva
- Acacia Pharma
- Acarix
- Adocia
- ASIT biotech
- Basilea Pharmaceutica
- BioPorto Diagnostics
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- MOLOGEN
- Nanobiotix
- Newron Pharmaceuticals
- Nuevolution
- Oncology Venture
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Photocure
- Pixium Vision
- Probiodrug
- Quantum Genomics
- RhoVac
- Ryvu Therapeutics
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma